↑↑ Click on the above“MedLive Neurology” to follow us ↑↑ Dopamine Dysregulation Syndrome (DDS) is a condition characterized by compulsive use of dopaminergic medications in patients with Parkinson’s disease undergoing long-term dopamine replacement therapy (DRT), with an average onset age of around 60 years. Currently, there are few reports on the incidence of DDS, not … Read more
Antibody-drug conjugates (ADCs) are rapidly emerging as a transformative approach in cancer treatment, due to their potential for targeted therapy, fewer side effects, broader application, and higher therapeutic index compared to traditional chemotherapy.While ADCs initially focused on hematological malignancies, there has been a clear shift towards solid tumor treatment, with approximately 90% of ADC trials … Read more
–01– Introduction Antibody-drug conjugates (ADCs) are known as “magic bullets”, precisely targeting tumor cells through antibodies to deliver cytotoxic drugs, combining the precision of targeted therapy with the potent lethality of chemotherapy. Over the past decade, ADCs have gradually matured in the treatment of solid tumors and hematological malignancies, becoming a revolutionary field in anti-tumor … Read more
Professor Li Xingshu from Fuzhou University, Professor Juyoung Yoon from Ewha Womans University, and Professor Zhang Hua from Henan Normal University have reviewed the relevant research on enhancing the biosafety of photodynamic therapy. Key Points of the Article: (1) Photodynamic therapy (PDT) is a non-invasive optical treatment method involving reactive oxygen species (ROS), characterized by … Read more
Click the blue text above to follow us Editor’s Note: With their unique mechanisms of action and powerful efficacy, Antibody-Drug Conjugates (ADCs) have become indispensable treatment methods for various solid tumors and hematological cancers, such as breast cancer. The core component that determines the efficacy of ADCs is undoubtedly the payload. Different payloads exhibit significant … Read more
Abstract:TROP2 (Trophoblast Cell Surface Antigen 2) is a tumor-associated antigen that is highly expressed in various solid tumors and has become a popular target for antibody-drug conjugates (ADCs). This article systematically introduces the biological characteristics of TROP2 and its expression profile in tumors, focusing on the molecular design, mechanism of action, and clinical efficacy of … Read more
Since the emergence of several new drugs for the treatment of solid tumors, such as larotrectinib and entrectinib, the concept of “broad-spectrum anti-cancer drugs” has officially entered public awareness. Years later, more and more broad-spectrum anti-cancer drugs have moved from the laboratory to clinical settings, officially ushering in this precise yet “broad-spectrum” era of cancer … Read more
Recently, the WeChat update has disrupted the release schedule, causing many readers to miss article updates. Please set “Fengkou Research” as a star ⭐ so we can move forward together and see each other every day! ADC, a potential new star in the field of innovative drugs In the vast starry sky of innovative drugs, … Read more
Cuproptosis is a novel copper-dependent programmed cell death mechanism, which centers on the interaction between copper ions and acylated proteins in the tricarboxylic acid (TCA) cycle, leading to protein aggregation and mitochondrial dysfunction, ultimately resulting in cell death. This mechanism provides new insights for cancer treatment, as the accumulation of copper ions in tumor cells … Read more
This article has a total of2229words, reading time:3-4 minutes ｜Author: MaxTom On May 29, 2025, Merck and Daiichi Sankyo jointly announced thevoluntary withdrawal of the market application for the HER3-targeted antibody-drug conjugate (ADC), Patritumab deruxtecan (HER3-DXd), which was originally seeking accelerated approval for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who … Read more